BNP Paribas Financial Markets’s Cyclerion Therapeutics CYCN Stock Holding History
Bought
Maintained
Sold
Other funds holding CYCN
VCM
KA
VFT
BNP Paribas Financial Markets's CYCN Position: Q1 2026 in Review
BNP Paribas Financial Markets held its Cyclerion Therapeutics (CYCN) position steady in Q1 2026 at 5 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #5770.
BNP Paribas Financial Markets first reported a position in CYCN in Q2 2019 and has held it in 22 quarters since. The position peaked at $34.8K in Q3 2019. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.
- BNP Paribas Financial Markets held 5 shares of Cyclerion Therapeutics worth $8 as of Q1 2026.
- BNP Paribas Financial Markets left its Cyclerion Therapeutics share count unchanged in Q1 2026.
- Cyclerion Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5770 holding.
- BNP Paribas Financial Markets first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 22 quarters since.
- BNP Paribas Financial Markets's Cyclerion Therapeutics position peaked at $34.8K in Q3 2019.
- 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.